NICE endorses Brainomix AI-enabled software in Stroke

  • New guidance from NICE, the globally respected health assessor, acknowledges the impact that Brainomix 360 has demonstrated on stroke care, expanding patient access to life-changing treatments
  • Brainomix was one of only two companies granted the highly coveted endorsement


The U.K. health assessor the National Institute of Health and Care Excellence (NICE) has issued guidance endorsing the use of Brainomix 360 (formerly known as e-Stroke) to help clinical decision making in stroke.

The artificial intelligence (AI)-powered tool from Oxford-based Brainomix was one of only two products to obtain this select endorsement amongst more than a dozen technologies that were assessed by NICE, the highly respected health evaluator with a stringent evidence-based approach, whose recommendations carry global significance.

The NICE guidance elevates the Brainomix 360 stroke platform, the European market leading solution now entering the US market, to an evidence generation framework, which enables stroke units across the UK to utilize the technology while further evidence is collected.

More than 100,000 strokes occur every year in the UK, making it is a leading cause of disability and one of the most common causes of early death.

The Health Technology Assessment (HTA) acknowledged that there is evidence showing that patients admitted to hospital with a suspected stroke had faster and improved access to treatment after using Brainomix 360. NICE have requested that further evidence be gathered to validate the significance of that link, along with cost effectiveness data.

Dr Michalis Papadakis, co-founder and CEO of Brainomix, commented: “We are very pleased to receive this endorsement from NICE, which is an acknowledgement of the critical role that our AI-powered software is playing in stroke care, helping clinicians make more confident decisions leading to more patients getting access to life saving treatments. Most importantly, this recommendation was driven by the emergence of powerful, real-world evidence demonstrating the transformative impact of Brainomix 360 on stroke treatment, mechanical thrombectomy in particular.”

Brainomix was the recipient of the prestigious NHS AI in Health & Care Award in 2020 enabling its Brainomix 360 stroke platform to be deployed across multiple UK stroke networks. An independent evaluation by the team at Health Innovation Oxford and Thames Valley as part of this award has been assessing the impact of the stroke AI platform across more than twenty-four (24) stroke centres and included tens of thousands of patients. This independent real-world impact evaluation will add further evidence to demonstrate the value of Brainomix 360 in the NHS.

A recent report from Health Innovation Oxford & Thames Valley (formerly known as Oxford Academic Health Science Network) found that the average thrombectomy treatment rate in hospitals with Brainomix 360 software was 55% higher than the national average – an uplift that reflects hundreds more patients receiving life-changing thrombectomy treatment and avoiding the long-term effects of stroke.

Dr Kiruba Nagaratnam, Consultant Stroke Physician and Clinical Lead for Stroke Medicine at the Royal Berkshire Hospital in Reading, commented: “We welcome this latest guidance from NICE, which reflects the clinical value that Brainomix 360 brings to stroke care – which we have been seeing since we first implemented the software in March 2020. Our recently published study showed that the implementation of Brainomix 360 not only improved our speed of treatment, but most notably, improved patient outcomes, with the number of patients achieving functional independence rising from 16% to 48%.”

The Brainomix 360 stroke platform has been widely adopted across England and is now used in the majority of stroke centres. The technology has also been deployed in more than 30 countries, including a national-level deployment in Wales and Hungary, and recently launched in the US following a series of FDA clearances.


More news and updates 

RSSL announces new Biotech Innovation Hub

RSSL, a leading pharmaceutical contract research organisation, has today announced plans to launch its new Innovation Hub, a dedicated platform to help small- and medium-sized biotech organisations de-risk and accelerate the development of cutting-edge products.

Aleta Biotherapeutics and Cancer Research UK announce first patient dosed in ALETA-001 Phase 1/2 clinical trial

The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001. ALETA-001 entering the clinic is a critical milestone toward treatment availability to improve CAR T-cell patient response when a complete response is not achieved or maintained.

UKHSA announced as first PACE collaboration to help tackle deadly antimicrobial resistance

Strategic partnership to support AMR innovators

PrecisionLife and Metrodora Institute partner to accelerate diagnosis of Long COVID

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases; targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

BugBiome secures investment for pioneering research in sustainable pest protection

BugBiome raises £310,000 in pre-seed investment from Cambridge Angels and Discovery Park Ventures. Investment enables a £330,000 Engineering Biology Grant from Innovate UK for cutting-edge agri-tech research leveraging the microbiome and engineering biology approaches.

Study reveals POLB 001 could be a $10 billion game changer for cancer patients

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS). Former Amryt Pharma team's arrival supports increasing focus upon Rare and Orphan Diseases

Demand for Golden Triangle lab space surges with highest annual volume since 2015

Demand for life sciences space in the ‘Golden Triangle’ surged in 2023, with the 925,000 sq ft of space representing the highest annual volume since 2015, according to the latest figures from Cushman & Wakefield.

New £100 million engineering biology fund

Six new Engineering Biology Mission Hubs and 22 Mission Awards, to transform solutions in areas like vaccine development, textile manufacturing and food production; New investments to unlock potential of engineering biology as part of the wider National Engineering Biology Programme

Pioneer Group’s regeneration plans for Cambridge’s Grafton Centre approved

Pioneer Group, a leading developer and operator of life science and high-tech campuses, has secured planning permission from Cambridge City Council, subject to S106, for the redevelopment of the Grafton Centre in the city.


More within